Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...

Background of Urgent Problem Prostate cancer is one of the most common cancers among men. Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer characterized by resistance to castration therapy. Radium-223 is an α-emitting radiopharmaceutical that has been shown to improve overall survival (OS) and reduce sk...